These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 17882256)

  • 1. Pathologically activated therapeutics for neuroprotection.
    Lipton SA
    Nat Rev Neurosci; 2007 Oct; 8(10):803-8. PubMed ID: 17882256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The chemical biology of clinically tolerated NMDA receptor antagonists.
    Chen HS; Lipton SA
    J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
    Tanović A; Alfaro V
    Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine.
    Lipton SA; Chen HS
    Cell Death Differ; 2004 Jan; 11(1):18-20. PubMed ID: 14647237
    [No Abstract]   [Full Text] [Related]  

  • 5. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond.
    Lipton SA
    Nat Rev Drug Discov; 2006 Feb; 5(2):160-70. PubMed ID: 16424917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence.
    Danysz W; Parsons CG
    Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S23-32. PubMed ID: 12973747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of memantine.
    Johnson JW; Kotermanski SE
    Curr Opin Pharmacol; 2006 Feb; 6(1):61-7. PubMed ID: 16368266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.
    Kornhuber J; Weller M; Schoppmeyer K; Riederer P
    J Neural Transm Suppl; 1994; 43():91-104. PubMed ID: 7884411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma.
    Seki M; Lipton SA
    Prog Brain Res; 2008; 173():495-510. PubMed ID: 18929130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memantine as a neuroprotective agent in early phases of psychosis.
    Fusar-Poli P; Pellegrini F; Cortesi M
    Med Hypotheses; 2007; 68(2):459-60. PubMed ID: 17005328
    [No Abstract]   [Full Text] [Related]  

  • 11. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists.
    Muir KW
    Curr Opin Pharmacol; 2006 Feb; 6(1):53-60. PubMed ID: 16359918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
    Lipton SA
    Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine: the next trend in academic performance enhancement?
    Ota KS; Godwin T
    J Am Osteopath Assoc; 2006 Jun; 106(6):358-9. PubMed ID: 16790543
    [No Abstract]   [Full Text] [Related]  

  • 14. S-Nitrosylation and uncompetitive/fast off-rate (UFO) drug therapy in neurodegenerative disorders of protein misfolding.
    Nakamura T; Lipton SA
    Cell Death Differ; 2007 Jul; 14(7):1305-14. PubMed ID: 17431424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of nitrite therapy in cerebral ischemia by NMDA receptor inhibition.
    Jung KH; Chu K; Lee ST; Park HK; Kim JH; Kang KM; Kim M; Lee SK; Roh JK
    Biochem Biophys Res Commun; 2009 Jan; 378(3):507-12. PubMed ID: 19056343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Modern aspects of investigation and clinical application of glutamatergic agents].
    Petrov VI; Onishchenko NV
    Eksp Klin Farmakol; 2002; 65(4):66-70. PubMed ID: 12449079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
    Lipton SA
    NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuing Alzheimer's disease drug therapy: why, when, and how.
    Crutchfield D
    Director; 2008; 16(1):19-21. PubMed ID: 19343870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lithium neuroprotection: molecular mechanisms and clinical implications.
    Rowe MK; Chuang DM
    Expert Rev Mol Med; 2004 Oct; 6(21):1-18. PubMed ID: 15488156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xenon as neuroprotectant in acute stroke?
    Altschuler EL
    Med Hypotheses; 2001 Feb; 56(2):227-8. PubMed ID: 11425293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.